Cefminox Sodium

Cefminox Sodium (CAS No.: 75498-96-3) is a semisynthetic cephamycin class beta lactamase stable cephalosporin derivative used primarily as a research tool in antimicrobial pharmacology and translational mechanism studies, with a functional profile that includes broad spectrum bactericidal activity through inhibition of bacterial cell wall biosynthesis and reported bioactivity in mammalian signaling contexts where it has been described as engaging prostacyclin receptor IP and PPAR gamma related pathways, accompanied by modulation of cAMP production, increased PTEN expression, and suppression of Akt mTOR signaling in experimental systems; within biomedical discovery workflows it is therefore commonly positioned at the interface of anti infective screening and pathway oriented phenotypic investigation, and although quantitative potency readouts can vary across organism, strain, and assay format, antibacterial effects for cephamycin and cephalosporin agents are typically evaluated by minimum inhibitory concentration paradigms spanning low micromolar to higher micromolar equivalent exposure windows in susceptible in vitro models, while receptor and signaling associated exploratory assays are generally interpreted in micromolar concentration domains unless otherwise established by assay specific validation, and in practical use it is applied in microbial susceptibility panels, mechanism of action studies, resistance biology experiments, inflammation and vascular remodeling related cell based assays, and selected rodent disease models including pulmonary vascular pathology paradigms, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.